Institut Jules Bordet
- Address
- Rue Heger Bordet 1, 1000 Brussels, Belgium
Institut Jules Bordet - Melanoma Research Center
Institut Jules Bordet is a distinguished oncology research institution specializing in advanced cancer therapeutics and immunotherapy trials. As a key participant in the EORTC Melanoma Group, the institute demonstrates particular expertise in developing novel treatment strategies for high-risk melanoma patients following surgical intervention.
- Adjuvant immunotherapy trials for high-risk Stage III melanoma
- Anti-PD-1 monoclonal antibody therapy with pembrolizumab (MK-3475)
- Biomarker-driven treatment approaches including PD-L1 expression analysis
- Recurrence-free survival outcomes in post-operative melanoma management
The center's research focus encompasses patients with complete resection of Stage IIIA, IIIB, and IIIC melanoma, targeting those with histologically confirmed lymph node metastases. Their clinical trial portfolio emphasizes adjuvant immunotherapy approaches, utilizing cutting-edge checkpoint inhibitor technology to prevent melanoma recurrence in surgically treated patients, with special attention to PD-L1 positive tumor populations.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 307 other sites in Belgium
Therapeutic Area Benchmark — Belgium
Select a therapeutic area to compare against other sites in Belgium.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Belgium
Market Share
Country: Belgium
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Institut Jules Bordet
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Adjuvant Pembrolizumab Versus Placebo in High-Risk Stage III Melanoma Post-Resection: A Randomized, Double-Blind Phase 3 EORTC Trial | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Jul 2015 | — |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Enzalutamide | 1 | Unknown | 2021-09-27 | 2021-09-27 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.